Pipeline

Recce Pharmaceuticals is addressing the historic lack of innovation in antibiotic drug development and the growing need for effective antibiotics.

Pipeline

Over Various Indications and Upcoming Inflection Points
Asset andRoute of administration
Indications
Discovery
Preclinical
Phase I
Phase II
Phase III
Market
R327 Topical*Wound infections including infected burns
Diabetic Foot Ulcer Infections
Pre-Clinical Programs* Various routes of administrationMycobacterium abscessus
Bacterial Sinusitis
Additional TBA

A Clinical Pathway to

Antibiotic Approval

There are three distinct phases of clinical evaluation prior to approval for new drugs:

Phase I

These studies are usually conducted in 20-80 healthy volunteers and aim to determine if the drug is safe, if it has any side effects and how it is metabolised and excreted.

Phase II

These studies are usually conducted in 20-80 unwell patients. The focus in Phase 2 study is on effectiveness and data on whether the drug works in people who have a certain disease or condition. Safety and short-term side effects continue to be evaluated. At the end of Phase II study the drug developer and the FDA will discuss the structure and size of the final phase.

Phase III

These studies enrol a much larger number of patients than Phase I and Phase II study. The aim is to gather more information about safety and effectiveness of the drug. Phase III studies look at use of the drug in different populations and different dosages and using the drug in combination with other drugs and how it interacts.